The Detroit Tigers are investing big in their bullpen, locking down a key reliever with a substantial contract. Tigers' management has agreed to a two-year, $19 million deal with right-handed pitcher Kyle Finnegan, a move that could significantly impact their pitching depth. But is this a wise investment?
Finnegan, a 34-year-old Detroit native, is set to earn a base salary of $8.75 million in 2026 and $8 million in 2027, with a mutual option for 2028 at $10 million. This contract also includes performance incentives, with Finnegan earning an additional $125,000 for each milestone of 40, 45, 50, and 55 games played.
His performance in 2025 was impressive, posting a 4-4 record with 24 saves and a 3.47 ERA across 56 relief appearances for both the Washington Nationals and the Tigers. And this is the part most people miss: Finnegan's ERA was even better after his mid-season trade to Detroit, dropping to 3.06 with 16 saves in 28 games.
The Tigers acquired Finnegan from Washington on July 31, giving up pitching prospects Josh Randall and R.J. Sales. This move strengthened Detroit's bullpen, which was a key factor in their playoff push. Finnegan's experience and success in the 2025 postseason, where he went 1-1 with a 3.68 ERA in six games, further highlights his value.
But here's where it gets controversial: Is Finnegan worth this substantial investment? His career record is 26-30 with a 3.55 ERA, which some may argue doesn't warrant a multi-million-dollar contract. However, his recent performance and postseason experience could be seen as a significant boost to the Tigers' bullpen.
What do you think? Is this a smart move by the Tigers, or should they have allocated their resources differently? Share your thoughts in the comments below!
